Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
2566.HK
Hong Kong Stock Exchange5.99
HKD
+0.27
- -
ISIN
CNE100006KF0
Return %
Stock
S&P500
1Y
-28.00
25.65
3Y
-21.70
70.81
5Y
-21.70
77.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Fu Hang
- Full Time Employees
- 1,794
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 23, Eighth Street Hangzhou People's Republic of China 310018
- IPO Date
- Nov 28, 2024
- Website
- china-gene.com
- Similar Companies
- Business
- Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacture, and marketing of gene-engineered and biochemical pharmaceuticals, with operations spanning the development of injectable and biologic therapies for oncology, hematology, and metabolic disease indications; the company markets a portfolio of therapeutics and related medical products through its GMP-compliant production facilities and regional sales networks. Headquartered in Hangzhou, China, the group pursues a diversified product strategy across its core categories, including recombinant and monoclonal antibody therapies, supportive care injectables for cancer patients, and select anticoagulant and antiemetic formulations; it participates in clinical development programs and seeks regulatory approvals for investigational assets in addition to commercial products. Founding year and long-standing regional footprint establish the company as a China-based biopharmaceutical producer with distribution channels and partnerships across domestic markets and selected international markets. The company’s structure includes research and development capabilities, manufacturing operations, quality assurance, regulatory affairs, and commercial functions, with subsidiaries and partnerships designed to extend product reach and pipeline execution. Main products and services include rhBMP-2 bone repair agents; neutropenia and chemotherapy-induced thrombocytopenia therapies; antiemetic injections for chemotherapy- and radiotherapy-induced nausea and vomiting; fulvestrant and other oncology agents; enoxaparin sodium and low molecular weight heparin injections for venous thromboembolism; palonosetron hydrochloride for antiemetic use; and ongoing development candidates such as monoclonal antibody therapies targeting cancer and metabolic disease indications, along with supporting devices and supply chain services for injectable therapeutics. Latest major company changes include progress on clinical development and regulatory milestones for novel assets, strategic collaborations or partnerships within the biopharmaceutical sector, enhancements to manufacturing capacity or process improvements, and announcements of IND approvals or trial initiations for new injections; the company also discloses updates on acquisitions, divestitures, or reorganizations as they occur within the last 1-2 years, reflecting a shifting strategic focus toward expanding the pipeline in oncology, hematology, and metabolic disease segments. Additional context shows activity across the industry segments of oncology therapeutics, hematology, and metabolic disease drugs, with target markets comprising healthcare providers, hospital networks, and specialty pharmacies in China and select international markets; geographic operations are anchored in China with potential outreach to regional markets, and the corporate structure reports parent-subsidiary relationships and collaborations, positioning the company as a growth-stage biopharmaceutical player with an emphasis on gene-engineered and biochemical modalities.